(Q39751307)

14 September 2017

title

Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation (English)

1 reference

14 September 2017

1 reference

Meena Sharma

1

1 reference

14 September 2017

Robert T Ownbey

series ordinal

2

1 reference

14 September 2017

Mahesh C Sharma

series ordinal

3

1 reference

14 September 2017

language of work or name

1 reference

15 January 2010

1 reference

Experimental and Molecular Pathology

14 September 2017

published in

1 reference

14 September 2017

volume

88

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

278-286

1 reference

Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tissue plasminogen activator expression in meningiomas and glioblastomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Urokinase-type plasminogen activator antigen and early relapse in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Biology and biochemistry of proteinases in tumor invasion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin induces and sustains dormancy of human primary tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Annexin II represents metastatic potential in clear-cell renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Role of Annexin-II in GI cancers: interaction with gastrins/progastrins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin receptor annexin II in vascular tumors including angiosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Increased expression of Annexin A2 in oral squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.001

10.1016/J.YEXMP.2010.01.001

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference